Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carfilzomib + Dexamethasone + KTX-1001 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carfilzomib | Kyprolis | PR-171 | Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov). | |
| Dexamethasone | Adexone | Desametasone | ||
| KTX-1001 | KTX 1001|KTX1001 | KTX-1001 is a selective inhibitor of NSD2 (MMSET), which potentially inhibits tumor cell growth and induces antitumor activity (Blood (2024) 144 (Supplement 1): 3370, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05651932 | Phase I | KTX-1001 CC-92480 + Dexamethasone + KTX-1001 Dexamethasone + KTX-1001 Dexamethasone + KTX-1001 + Pomalidomide Carfilzomib + Dexamethasone + KTX-1001 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | CAN | 0 |